AMRN

Vascepa

Cardiovascular disease (triglyceride lowering)

Quarterly Sales (Approved)

Exp Date

November 3, 2020 (Est)

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Quarterly Sales for Vascepa used to lower cholesterol (FDA-approved drug) 


WHAT IS THE CATALYST EVENT?

  • Quarterly Sales


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA 


PRESS RELEASES

PRESENTATIONS

MECHANISM OF ACTION/RATIONALE

  • Studies suggest that EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity.

  • FDA Drug Label (slide 5, section 12.1)

Updated by HC

#AMRN, #Vascepa, #Vascepa, #icosapent_ethyl

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

AMRN's Q2 VASCEPA® Net Sales...

AMRN reported a $135.3 million in net total revenue in Q2 2020, an increase of 34% over Q2 2019, resulting in H1 2020 net total revenue of $290.3 million, an increase of 67% over H1 2019. In addition...

AMARIN ANDA LITIGATION UPDATE:...

In our Amp Patent Investor subscription forum, I provide my analysis of the possible affect on the appellate court's ruling, of the recent scientific publication by the Reduce-It trial's principal inv...

Jackpot...

BINGO #winner #ZGNX #AMRN #AIMT...

AMRN Litigation Update | Possi...

Dr. Vacchiano, JD, PhD, analyzed the complex factual, regulatory and legal issues specifically related to Amarin's possible attempt to obtain a preliminary injunction from the court to stop a possible...

Experienced biotech patent att...

Check out my 20 minute video about the ongoing AMRN ANDA appeal. It includes valuable information include key dates in the litigation as well as the #1 misconception of biotech investors regarding thi...

AMRN Litigation Update - 5/19/...

On 5/19/20 the BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO), the largest trade organization representing biotech companies and Universities filed an amicus brief in the Amarin appeal. The brief relates...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon